Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | CLDN18.2 |
Clinical data | |
Trade names | Vyloy |
Other names | IMAB362; claudiximab |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Zolbetuximab, sold under the brand name Vyloy, is a monoclonal antibody against isoform 2 of Claudin-18 used for the treatment of gastric cancer. [1] It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab was developed by Ganymed Pharmaceuticals AG. [2] Astellas Pharmaceuticals acquired the rights to zolbetuximab in December 2016, when it acquired Ganymed Pharmaceuticals. [3]
Zolbetuximab was in phase III clinical trials as of November 2021 [update] for gastric cancer. [4] [5] [6] [7]
In Japan, zolbetuximab is approved for the treatment of people with CLDN18.2-positive, unresectable, advanced, or recurrent gastric cancer. [1] [8]
Zolbetuximab is the international nonproprietary name. [9]
{{
cite journal}}
: CS1 maint: DOI inactive as of January 2024 (
link)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | CLDN18.2 |
Clinical data | |
Trade names | Vyloy |
Other names | IMAB362; claudiximab |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
(what is this?) (verify) |
Zolbetuximab, sold under the brand name Vyloy, is a monoclonal antibody against isoform 2 of Claudin-18 used for the treatment of gastric cancer. [1] It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab was developed by Ganymed Pharmaceuticals AG. [2] Astellas Pharmaceuticals acquired the rights to zolbetuximab in December 2016, when it acquired Ganymed Pharmaceuticals. [3]
Zolbetuximab was in phase III clinical trials as of November 2021 [update] for gastric cancer. [4] [5] [6] [7]
In Japan, zolbetuximab is approved for the treatment of people with CLDN18.2-positive, unresectable, advanced, or recurrent gastric cancer. [1] [8]
Zolbetuximab is the international nonproprietary name. [9]
{{
cite journal}}
: CS1 maint: DOI inactive as of January 2024 (
link)